Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

Moderna expects AI to help it become even faster and more efficient in drug development. Medtronic recently signed a deal with Nvidia that could bring it a step closer to dominance in AI healthcare.

Better Healthcare AI Buy: Moderna vs. Medronic

Albemarle

Coca-Cola

NextEra Energy

General Dynamics

JPMorgan Chase & Co

Procter & Gamble

Passive investing is a great way to create long-term returns. It can be as simple as identifying dividend stocks to buy and hold for the next decade or more.

7 Dividend Stocks to Buy and Hold for the Next Decade

Abbott Labs

Automatic Data Processing

Clorox

Ecolab

Essex Property Trust

Hormel Foods

Nordson

Realty Income Corp

Sherwin-Williams

S&P Global

Stanley Black & Decker

Sysco

T. Rowe Price Group

V.F.

Walgreens

Exxon Mobil

NOBL mustered a comeback in March finishing the month up 0.99%, the ETF is up 1.79% after Q1 2023. Q2 is off to a good start as NOBL is up 1.52% through April 25th.

My Best Dividend Aristocrats For May 2023

Medtronic (MDT) closed at $89.69 in the latest trading session, marking no change from the prior day.

Medtronic (MDT) Flat As Market Sinks: What You Should Know

Resolution follows the recent FDA approval of the MiniMed™ 780G system featuring the world's first and only automated insulin delivery system with real-time meal detection technology* DUBLIN , April 25, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) lifted the warning letter received at the company's Diabetes headquarters in Northridge, California, in December 2021. This follows on the heels of last week's FDA approval of the MiniMedTM 780G system, the world's first and only automated insulin delivery system with meal detection technology* that provides automatic adjustments and corrections† to glucose levels every 5 minutes.

Medtronic Diabetes resolves warning letter, clearing path for future innovations

Bristol-Myers

FedEx

Fiserv

Altria

Target

Q1 Earnings Season Scorecard is included in today's Research Daily in addition to new research reports on Bristol-Myers (BMY), Medtronic(MDT) and Altria Group (MO).

Q1 Earnings Scorecard and Fresh Analyst Reports for Bristol-Myers, Medtronic & Altria Group

NVIDIA

Medtronic will use Nvidia AI technology to detect precancerous tissue earlier -- and improve patient outcomes. The medical device giant sees AI as the key to personalized medicine.

Medtronic Is Partnering With Nvidia to Create Potentially Game-Changing Tech. Is the Stock a Buy?

An analyst at Wells Fargo upgraded Medtronic's stock today. In response, the medtech giant's shares edged higher.

Why Medtronic Stock Edged Higher Today

The med-tech companies have gotten a lot of attention lately, and Medtronic (NYSE: MDT) is included. The rebound in procedures and healthcare services following the pandemic drives a rebound in the industry amplified by innovation.

Medtronic: Reversal In-Play For This High-Yield Stock

Wells Fargo analysts raised their price target for shares of the medical-technology company to $100 from $77.

Medtronic Stock Has Room to Rise as 'Major Milestone' Is Reached

Available in Europe since 2020, this new system delivers the strongest clinical outcomes and best user experience to-date within the Medtronic family of pumps DUBLIN , April 21, 2023 /PRNewswire/ --  Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its MiniMed™ 780G system with the Guardian™ 4 sensor requiring no fingersticks while in SmartGuard™ technology‡. This milestone marks the approval of the only system with meal detection technology* that provides automatic adjustments and corrections† to sugar levels every 5 minutes§ for both basal (background) and bolus (mealtime) insulin needs.

FDA Approves Medtronic MiniMed™ 780G System - World's First Insulin Pump with Meal Detection Technology* Featuring 5-Minute Auto Corrections†§

Novo Nordisk

Novo Nordisk boasts a strong expertise in diabetes and other critical areas of medicine. Medtronic offers a rich and growing portfolio of products as well as a solid dividend.

Got $5,000? 2 Unstoppable Stocks to Buy and Hold Forever

Good financial results from two peers lifted sentiment on the medical-device maker. Medtronic has also been doing well lately, and those companies' performances indicate more growth could be coming.

Why Medtronic Stock Soared More Than 4% Higher Today

Aurinia Pharmaceuticals

Reata Pharmaceuticals

Reata Pharmaceuticals earned approval for its first drug in February, and its stock price has been soaring ever since. The first new drug Aurinia Pharmaceuticals launched got off to a rocky start, but a strong end to 2022 caused the stock to soar this year, Orchestra BioMed is a medical technology developer that has an important partnership with Medtronic, the world's largest medical device manufacturer.

3 Stocks That Already Doubled in 2023 and Could Keep Climbing

Medtronic's investors endured a steep selloff in early March but formed a constructive bottom, lending optimism to its battered holders. We assessed that MDT buyers returned to defend the lows last seen in December and not give them up.

Medtronic: Buyers Strike Back

Intuitive Surgical

Varex Imaging

As the population of our country continues to age, treatments and disease detection will continue to increase in demand. Additionally, improvements in imaging, robotics, and AI technology continue to give scientists new tools to make better medical devices.

News for Medtronic Stock (MDT)